Dr. Cohen Discusses CAR T-Cell Therapy in MCL

Video

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL).

CAR T-cell therapy is being explored as a treatment option for patients with relapsed/refractory MCL. Currently, the phase II ZUMA-2 trial is evaluating the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory MCL who no longer respond to treatment. Cohen says that at Winship Cancer Institute, patients with MCL enrolled on this trial have done very well, which suggests that there is a place for this treatment approach in the MCL landscape.

Like other lymphoma subtypes, the challenge is finding where CAR T-cell therapy fits into the treatment algorithm, Cohen says. In aggressive lymphomas, it is easier to determine this, he explains, because there are not many novel therapies available to offer. For those patients who have progressed after an autologous stem cell transplant or who are ineligible for transplant, CAR T-cell therapy can be a potential treatment option. However, he adds that there are several drugs available and in development for MCL that do not require the intensive treatment that CAR T-cell therapy does, says Cohen, making the placement for this therapy even more of a challenge.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.